6160:HKG
BeOne Medicines AG
HK$176.80
arrow_upward
+0.97%(+1.70) 1D
May 29, 4:08:25 PM GMT+8 · HKD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 6160...
Open
HK$176.80
High
HK$180.00
Low
HK$172.00
Mkt. cap
283.50B
Avg. vol.
3.86M
Volume
10.29M
P/E ratio
65.66
52-wk high
HK$229.40
52-wk low
HK$143.30
EPS
HK$2.69
Shares outstanding
1.43B
No. of employees
12K
Open
HK$176.80
High
HK$180.00
Low
HK$172.00
Mkt. cap
283.50B
Avg. vol.
3.86M
Volume
10.29M
P/E ratio
65.66
52-wk high
HK$229.40
52-wk low
HK$143.30
EPS
HK$2.69
Shares outstanding
1.43B
No. of employees
12K
News stories
From sources across the web
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com
AI content may include mistakes. Learn more